Onset: 20-45 minutes (faster than modafinil, comparable to amphetamine IR).

Peak: ~1-2 hours after dose. Effect feels like sharp, focused attention with mild adrenergic edge. Less euphoric than Adderall, less "wake-promoting" than modafinil, more "lock-in" focus on the task in front of you. Some users describe it as "caffeine-like but with more cognitive teeth."

Plateau: Brief — only ~2-3 hours of solid plateau before taper begins. This is the defining clinical feature of Ritalin IR vs longer-acting alternatives.

Taper / crash: Noticeable fade at 3-4 hours post-dose. Crash can include fatigue, irritability, mild dysphoria, and rebound focus loss — more pronounced than modafinil's gradual fade. Drives the need for a second (and often third) dose to maintain coverage across a workday.

Characteristic effects:

• Sharp narrow attentional focus — easier to lock onto a single task, harder to switch flexibly than baseline (more "tunnel" feel than modafinil, less than amphetamine)
• Reduced appetite (moderate — less than Adderall, more than modafinil)
• Mild HR elevation (~5-15 bpm) and BP elevation (~3-7 mmHg systolic)
• Dry mouth, mild sympathomimetic feeling
• Less euphoria than amphetamines — most users don't describe Ritalin as "fun" the way Adderall can feel
• Mild jaw tension / bruxism in a subset
• Sleep disruption if dosed after ~2 PM

Honest variability: Subjective response is more variable than modafinil. ~15-20% of users dislike Ritalin specifically (vs amphetamines or modafinil) — citing the narrow window, the sharp crash, or the "mechanical" feel. CES1 polymorphism may explain part of this — fast hydrolyzers get sub-therapeutic exposure on standard doses.

• Tolerance buildup: Moderate. Faster than modafinil, slower than amphetamines. Daily users frequently report needing dose increases over months to maintain initial subjective effect, though clinical ADHD efficacy on objective measures appears more durable than subjective effect.
• Mechanism of tolerance: Postsynaptic dopamine receptor downregulation; presynaptic adaptation; possibly modest CES1 induction in a subset.
• Recommended cycle: Intermittent / on-demand use minimizes tolerance. For ADHD treatment: weekend washouts ("drug holidays") are common in pediatric protocols and help reset tolerance + recover appetite/sleep.
• Reset protocol: 1-2 weeks off restores most of acute effect. Long-term receptor changes from years of daily use take longer to normalize.
• Compared to amphetamines: MPH-class generally has lower tolerance trajectory and lower abuse liability than amphetamine-class — one of the core reasons MPH is preferred first-line in pediatric populations.

Synergistic with

• l-theanine 200mg co-administered: Smooths adrenergic edge, reduces anxiety, doesn't blunt focus. Same logic as the modafinil + theanine stack. Already in Dylan's V4 baseline.
• Magnesium glycinate (already V4): Helps with bruxism/tension that some users get on stimulants.
• Citicoline (already V4): Cholinergic support during stimulant-driven sustained attention; theoretically synergistic.
• Caffeine: Layers fine but doubles cardiovascular load. Unnecessary if MPH is already on board.

Avoid stacking with

• Modafinil — overlapping DAT inhibition, cumulative HR/BP load, no additive cognitive benefit. If considering both, alternate days at most. Same-day stacking not advised.
• Other classical stimulants daily (Adderall, Vyvanse, Focalin) — additive cardiovascular + dopaminergic load with diminishing cognitive return, escalating tolerance and abuse liability.
• MAO inhibitors (non-selective: phenelzine, tranylcypromine) — risk of hypertensive crisis. Selegiline at low MAO-B-selective doses (1-2.5mg) is fine.
• Yohimbine, high-dose synephrine, ephedrine — stacked sympathomimetic = anxiety + BP spike + arrhythmia risk.
• Bupropion at high dose — additive seizure threshold reduction; clinical use possible but cautious.

Neutral / safe co-administration

• All of Dylan's V4 supplements (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vitamin C) — no significant interactions.
• Creatine, omega-3s — neutral.
• Most peptides (Semax, Selank, BPC-157, TB-500) — neutral.

MPH metabolic profile:

• Primary: CES1A1-mediated de-esterification to inactive ritalinic acid
• Minimal CYP involvement — small contribution from CYP2D6 (p-hydroxylation) but clinically negligible
• Renal excretion >78% as ritalinic acid

Clinically significant interactions:

1. MAOIs (non-selective): Contraindicated. Hypertensive crisis risk. 14-day washout before/after.
2. Coumarin anticoagulants (warfarin): MPH may increase warfarin levels via mild hepatic enzyme effects — monitor INR.
3. TCAs, SSRIs, SNRIs: Combination usable (common in psychiatry) but watch for serotonergic + adrenergic synergy. Mild clinical caution; no absolute contraindication.
4. Anticonvulsants (phenytoin, primidone, phenobarbital): MPH may increase plasma levels; monitor.
5. Clonidine combination: Historically flagged for cardiovascular concern; modern data largely reassuring but still cautious.
6. Alcohol: Co-ingestion produces ethylphenidate (active metabolite via transesterification). Increases stimulant load and toxicity risk. Dylan: zero alcohol baseline, non-issue.
7. Vasopressors / decongestants (pseudoephedrine, phenylephrine): Additive sympathomimetic, BP elevation.

Crucially: MPH's minimal CYP involvement means far fewer drug-drug interactions than modafinil (no CYP3A4 induction, no contraceptive efficacy reduction, no opioid potency reduction). This is one of MPH's underrated practical advantages.

CES1A1 polymorphism:

• The G143E variant (rs71647871) reduces CES1 enzymatic activity. Carriers (~3-4% of Caucasians, higher in some populations) clear MPH more slowly → higher exposure on standard dose. May explain part of inter-individual subjective variability.
• Dylan's 23andMe (June 2026) will not directly provide CES1 G143E status (not commonly reported), but raw data via Promethease may include it.

CYP2D6: Minor pathway for MPH; PM status doesn't dramatically affect MPH itself. Relevant only if Dylan is co-prescribed CYP2D6 substrates.

COMT Val/Met: As with all dopaminergic enhancers — Val/Val (faster DA clearance) tends to respond more robustly; Met/Met more sensitive to anxiety side effects.

DAT1 (SLC6A3) VNTR: 9-repeat carriers may show different MPH response; literature mixed, not clinically actionable.

For Dylan: only realistic path is US telehealth Rx with legitimate clinical evaluation. A 20yo male with no prior ADHD treatment history, no documented childhood symptoms, and current functional output described as 6-12 hours of cognitive work daily would have a hard time obtaining ADHD Rx without genuine clinical workup. Modafinil's gray-market availability + lower brain-dev concern makes it the dominant practical choice.

Baseline (before starting)

• Resting HR + BP (3-day morning average) — MPH typically adds 5-15 bpm and 3-7 mmHg systolic
• ECG baseline if any family history of arrhythmia, structural heart disease, or sudden cardiac death; otherwise optional but reasonable
• TSH, fT4 — hyperthyroidism mimics stimulant effects and is a relative contraindication
• Anxiety baseline (GAD-7 or daily 1-10 VAS)
• Sleep onset time + quality (7 days pre-dose for comparison)
• Appetite VAS + body weight
• CES1 G143E status (from 23andMe raw data via Promethease) if available — guides starting dose

During use

• Daily: BP + HR (first 2 weeks), then weekly
• Daily: appetite, sleep onset, mood during titration
• Weekly: subjective focus VAS on-day vs off-day if used intermittently
• Monthly: weight
• 3 months: repeat BP, full bloodwork (liver panel, lipids, fasting glucose, HbA1c)
• Annual: ECG if used long-term + cardiovascular review

Post-cycle (if cycled)

• Sleep architecture restoration check (1-2 nights off should normalize)
• Appetite rebound check
• Subjective baseline cognition vs on-drug — calibrates real benefit vs habituation